Establishing outcome domains for evaluating treatment of acute and chronic gout.
OBJECTIVE
Novel therapies for gout have recently been developed which has prompted considerable efforts in defining the relevant outcomes for measurement in intervention trials of gout. This review summarizes the consensus exercises refining domains for measurement and the work of individual groups in assessment of the validity of measurement tools for these domains.


RESULTS
Recent publications have focused on the consensus exercises and validation studies of measurement tools, particularly in relation to tophus size and imaging.


CONCLUSIONS
Consensus on potential outcome domains has been achieved, but measuring these domains requires further validation in observational studies and confirmation of relevance from people with gout. Further work is also required in refining measurements of tophus size and imaging scores. The role of a response criteria measure is also yet to be defined, especially in relation to reduction in flare frequency, or whether composite criteria are necessary.
Grainger
Rebecca
R
Department of Medicine, Wellington School of Medicine & Health Sciences, University of Otago, Wellington 6242, New Zealand.
Taylor
William J
WJ
D000208:Acute Disease / Q000534:rehabilitation; D002908:Chronic Disease / Q000188:drug therapy / Q000534:rehabilitation; D002986:Clinical Trials as Topic; D023381:Endpoint Determination; D006073:Gout / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D007596:Joints / Q000187:drug effects / Q000503:physiopathology; D011788:Quality of Life; D016896:Treatment Outcome; D014527:Uric Acid; D014528:Uricosuric Agents
D014528:Uricosuric Agents; D014527:Uric Acid